CLINICAL AND IMMUNOLOGICAL PREDICTORS AND THEIR ROLE IN THE PROGRESSION OF NONSPECIFIC INTERSTITIAL PNEUMONIA
DOI:
https://doi.org/10.5281/zenodo.17291360Keywords:
nonspecific interstitial pneumonia, clinical predictors, immunological markers, IL-6, TGF-β, autoantibodies, progressive fibrosing interstitial lung disease, biomarkers, immunopathogenesis, prognosisAbstract
Nonspecific interstitial pneumonia (NSIP) is a heterogeneous subtype of interstitial lung disease characterized by varying degrees of inflammation and fibrosis. Although many patients respond favorably to corticosteroids and immunosuppressive therapy, a significant proportion develop progressive pulmonary fibrosis (PPF), which leads to a steady decline in lung function and poorer survival outcomes. Early identification of clinical and immunological predictors is therefore crucial for timely intervention and improved prognosis.
References
1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–748.
2.Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J. 2009;33(1):68–76.
3.Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):285–292.
4.Ryerson CJ, Kolb M. The overlap of idiopathic pulmonary fibrosis and connective tissue disease–related interstitial lung disease. Curr Opin Pulm Med. 2020;26(5):442–450.
5.Brown KK, Flaherty KR, Cottin V, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the INBUILD trial. Lancet Respir Med. 2020;8(5):453–460.
6.Kim HJ, Lee JH, Ryu YJ, et al. Cytokine profiles and disease progression in nonspecific interstitial pneumonia. Respir Res. 2022;23(1):78.
7.Tzouvelekis A, Gomatou G, Bouros D. Biomarkers in idiopathic interstitial pneumonias: Unlocking personalized treatment. Eur Respir Rev. 2021;30(162):210031.
8.Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive interstitial lung diseases: Subgroup analyses by diagnosis in the INBUILD trial. Eur Respir J. 2021;57(3):2002513.
9.Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.
10.Sakamoto K, Taniguchi H, Kondoh Y, et al. Factors influencing survival in patients with nonspecific interstitial pneumonia. Eur Respir J. 2011;38(6):1424–1432.
11.Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
12.Gagiannis D, Steinestel J, Hackenbroch C, et al. Cytokine profiles in patients with idiopathic interstitial pneumonias: Implications for prognosis and treatment response. Front Immunol. 2023;14:1121439.
13.Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
14.Cerri S, Monari M, Guerrieri A, et al. Prognostic value of YKL-40 and CXCL13 in idiopathic and secondary NSIP. Chest. 2020;158(3):1125–1136.
15.George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925–934.
